There are many recent advances in insulin treatment of type 1 diabetes, however after a meal
sugars are always a concern. There is a drug Exenatide (Byetta) which is FDA approved to
treat people with type 2 diabetes which helps correct their glucoses (sugars) after meals.
This study is going to test whether this drug can improve the after meal sugars in people
with new onset type 1 diabetes. To test this you will be given a dose of exenatide (1.25 mcg)
and long acting insulin or inulin alone before the boost. There is also a placebo group
(healthy subjects) who do not get any medication before the boost. Insulin levels and other
hormones that affect blood glucose as well as your sugar will be measured by a series of
blood tests. The role exenatide as compared to insulin alone will be examined to prevent low
blood sugars which might occur because of food staying longer in the stomach than usual or
due to the suppression of a hormone called glucagon which increases blood sugar. If you
qualify you will be given exenatide (Byetta 1.25 mcg) along with insulin or insulin alone.
You and the researchers will not know which dose you are taking at any single visit. A total
of 20 people in which some will be children aged 12- 18 years will participate, being
diagnosed within 3 months of having been found to have type 1 diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)